Lorrain Daniel S. 4

What Happened
Daniel S. Lorrain, Chief Scientific Officer of Contineum Therapeutics, sold 4,170 shares on June 1, 2026. The shares were disposed for a weighted average price of $13.16 per share, totaling approximately $54,862. The sale was reported as an open-market or private sale (code S).

Key Details

• Transaction date: 2026-06-01 (filed the same day).
• Price: weighted average $13.16; individual sale prices ranged from $12.995 to $13.360 (report notes multiple transactions).
• Total proceeds: ~$54,862.
• Shares owned after the transaction: not specified in the filing.
• Footnotes of note:
  • F1: Transactions effected pursuant to a 10b5-1 trading plan adopted Sept 23, 2025.
  • F2: Price is a weighted average; reporting person will provide breakdown on request.
  • F3: Ownership figures in the filing (where shown) include 3,268 shares purchased via the company ESPP on May 15, 2026.
• Filing timeliness: filing date equals transaction date (no late filing indicated).

Context
This was a sale executed under a pre-established 10b5-1 plan, which typically schedules trades in advance and can indicate routine disposition rather than new CEO insider timing. For retail investors, purchases often carry clearer signals about insider conviction; sales can be routine or for personal reasons. If you want exact per-trade details or current insider holdings, the filer offers to provide a breakdown of the individual sale prices on request.